UBS Group »

Halozyme Therapeutics Inc Note 1.000 8/1 shares owned by UBS Group

Quarter-by-quarter ownership of Halozyme Therapeutics Inc Note 1.000 8/1 shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Halozyme Therapeutics Inc Note 1.000 8/1

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics Inc Note 1.000 8/1 held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics Inc Note 1.000 8/1 by UBS Group

Quarter filed Position value Share count Share price at filing
2025-09-30 $1.9k 1.3k 1.41
2025-06-30 $762 670 1.14
2025-03-31 $856 670 1.28
2023-12-31 $1.9k 2.0k 0.93

More positions owned by UBS Group

Spdr S&p 500 Etf Tr Tr Unit (SPY)
NVIDIA Corporation (NVDA)
Microsoft Corporation (MSFT)
Apple (AAPL)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Amazon (AMZN)
Broadcom (AVGO)
Meta Platforms Cl A (META)
Alphabet Cap Stk Cl A (GOOGL)
JPMorgan Chase & Co. (JPM)
Alphabet Cap Stk Cl C (GOOG)
Ubs Group SHS (UBS)
Tesla Motors (TSLA)
Ishares Tr Russell 2000 Etf (IWM)
Visa Com Cl A (V)

View all positions for UBS Group

Top funds holding Halozyme Therapeutics Inc Note 1.000 8/1

Millennium Management
LMR Partners
Calamos Advisors
Camden Asset Management
Balyasny Asset Management
DLD Asset Management
Point72 Asset Management
Davidson Kempner Capital Management
Jpmorgan Chase & Co
Jain Global
Nuveen
Lazard Asset Management
State Street Corporation
Absolute Investment Advisers
Citadel Advisors

View all funds holding Halozyme Therapeutics Inc Note 1.000 8/1